Roivant Unveils An Autoimmune-Focused 'Vant' At Inaugural Pipeline Day

 
• By Jessica Merrill

Immunovant is Roivant's 10th drug development-focused firm, progressing RVT-1401, an antibody targeting neonatal Fc receptor (FcRn) in immunoglobulin-mediated autoimmune diseases. Roivant showcased the budding pipeline of its growing family of companies, which now has 12 "vants."

Development Attainment Motivation Career Growth Concept. Mans Hand Reaching For Red Ladder Leading To A Blue Sky

More from Strategy

More from Business